{'fraction_non_alphanumeric': 0.04019746121297602, 'fraction_numerical': 0.028913963328631876, 'mean_word_length': 5.142857142857143, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Efficacy and safety of rituximab in marginal zone lymphoma : a meta-analysis of 13 studies

Background: Rituximab had been reported effective on follicular lymphoma. Marginal zone lymphoma and follicular lymphoma both derived from B cell lymphoma. This meta-analysis aimed to evaluate the effectiveness and safety of rituximab treatment in marginal zone lymphoma patients. Methods: Two investigators searched for eligible studies in MEDLINE, Embase and Cochrane Library electronic databases up to November 2015, independently. The patients used rituximab monotherapy were included. We used overall response rate (ORR) and complete response (CR) to evaluate the efficacy of rituximab. Statistical heterogeneity was calculated by using the I2 P statistic and Cochrane’s Q test. We used random-effects models if I2 > 50% or P < 0.1. Otherwise, we used fixed-effects models. Results: Thirteen studies which included 237 patients were eligible in the meta-analysis. The ORR was 81% (95% CI=72-88%, 13 studies including 237 patients) and CR rate was 50% (95% CI=39-61%, 13 studies including 237 patients). As for toxicities, the most frequent nonhematologic toxicity was mild infusion-related symptoms. Conclusions: In this meta-analysis, available evidence suggests that rituximab seems to be a safe and effective therapy for marginal zone lymphoma. Therefore, rituximab provides a good way to treat marginal zone lymphoma.